- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lymphomas | Clinical
FDA Clears Study of Novel CAR T-Cell Therapy for Aggressive B-Cell Lymphoma
January 24, 2023
An investigational new drug application for IMPT-314 has been cleared by the FDA. A phase 1/2 trial investigating the agent will be initiated in early 2023.
Evaluating Glofitamab as a Potential Option for Patients With R/R LBCL
January 24, 2023
Cyrus M. Khan, MD, discusses the mechanism of action of glofitamab and its potential use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.
Perez on Real-World Pola-BR Treatment Outcomes in Patients with R/R LBCL
January 16, 2023
In an interview with Targeted Oncology, Ariel Perez, MD, explained the outcomes of patients with R/R large B-cell lymphoma who were treated with Pola-BR in the real-world setting, and the key takeaways from a single-institution study.
Samhouri Discusses Practice Changing Data in the DLBCL Space
January 13, 2023
In an interview with Targeted Oncology, Yazan Samhouri, MD, discussed new agents, clinical trials, and developments creating change in diffuse large B-cell lymphoma, as well as the key takeaways from ASH 2022.
Addition of Polatuzumab to R-CHOP Improves Outcomes for Patients With DLBCL
January 10, 2023
In an interview with Targeted Oncology, Gustavo Fonseca, MD, FACP, discussed the positive health-related quality of life findings in patients with diffuse large B-cell lymphoma from the POLARIX study.
FDA Accepts BLA and Grants Priority Review for Glofitamab in R/R LBCL
January 06, 2023
Based on data from a phase 1/2 study, a biologics license application has been accepted for glofitimab and the product has been granted priority review to for relapsed/refractory large B-cell lymphoma.
Glofitamab Leads to Durable Complete Remissions in Relapsed/Refractory LBCL
January 06, 2023
In an interview with Targeted Oncology, Cyrus M. Khan, MD, further discussed the background of the phase 1/2 trial and the potential use of glofitamab for patients with large B-cell lymphoma in the future.
Phase 2 Studies of Odronextamab Elicit High Overall Responses in DLBCL and FL
January 05, 2023
In the diffuse large B-cell lymphoma and follicular lymphoma cohorts of the ELM-1 and ELM-2 trials, odronextamab led to high overall response rates.
Durable Efficacy and Safety Seen With Tisagenlecleucel in R/RAggressive B-Cell
December 16, 2022
Tisagenlecleucel led to durable efficacy and safety in the real-world setting for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
HD-ASCT Shows Longer Survival Vs Non-Myeloablative Chemoimmunotherapy in Primary CNS Lymphoma
December 13, 2022
An extended progression-free survival and 54% reduction in the risk of death was shown with high-dose chemotherapy autologous stem cell transplantation consolidation therapy vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.